iAnthus Capital Holdings Past Earnings Performance
Past criteria checks 0/6
iAnthus Capital Holdings has been growing earnings at an average annual rate of 20.3%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually. Revenues have been growing at an average rate of 8.9% per year.
Key information
20.3%
Earnings growth rate
59.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 8.9% |
| Return on equity | n/a |
| Net Margin | -32.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
The Market Doesn't Like What It Sees From iAnthus Capital Holdings, Inc.'s (CSE:IAN) Revenues Yet As Shares Tumble 33%
Nov 03
Improved Revenues Required Before iAnthus Capital Holdings, Inc. (CSE:IAN) Stock's 33% Jump Looks Justified
Sep 10Benign Growth For iAnthus Capital Holdings, Inc. (CSE:IAN) Underpins Stock's 40% Plummet
Jul 26iAnthus Capital Holdings, Inc. (CSE:IAN) Stock Catapults 50% Though Its Price And Business Still Lag The Industry
May 05iAnthus Capital Holdings, Inc. (CSE:IAN) Stocks Pounded By 29% But Not Lagging Industry On Growth Or Pricing
Feb 29iAnthus Capital Holdings, Inc. (CSE:IAN) Stock's 33% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Apr 17Is iAnthus Capital Holdings (CSE:IAN) Using Debt Sensibly?
Feb 28Is iAnthus Capital Holdings (CSE:IAN) A Risky Investment?
Aug 25Revenue & Expenses Breakdown
How iAnthus Capital Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 165 | -54 | 69 | 0 |
| 30 Jun 24 | 168 | -62 | 73 | 0 |
| 31 Mar 24 | 163 | -72 | 77 | 0 |
| 31 Dec 23 | 158 | -77 | 78 | 0 |
| 30 Sep 23 | 155 | -102 | 77 | 0 |
| 30 Jun 23 | 152 | -104 | 81 | 0 |
| 31 Mar 23 | 157 | -458 | 109 | 0 |
| 31 Dec 22 | 163 | -449 | 114 | 0 |
| 30 Sep 22 | 172 | -433 | 120 | 0 |
| 30 Jun 22 | 182 | -426 | 121 | 0 |
| 31 Mar 22 | 193 | -68 | 97 | 0 |
| 31 Dec 21 | 202 | -77 | 97 | 0 |
| 30 Sep 21 | 201 | -77 | 86 | 0 |
| 30 Jun 21 | 193 | -87 | 87 | 0 |
| 31 Mar 21 | 173 | -96 | 87 | 0 |
| 31 Dec 20 | 152 | -313 | 92 | 0 |
| 30 Sep 20 | 133 | -547 | 95 | 0 |
| 30 Jun 20 | 115 | -534 | 103 | 0 |
| 31 Mar 20 | 99 | -519 | 108 | 0 |
| 31 Dec 19 | 78 | -305 | 95 | 0 |
| 30 Sep 19 | 53 | -61 | 85 | 0 |
| 30 Jun 19 | 32 | -58 | 61 | 0 |
| 31 Mar 19 | 13 | -84 | 43 | 0 |
| 31 Dec 18 | 3 | -62 | 35 | 0 |
| 30 Sep 18 | 0 | -53 | 27 | 0 |
| 30 Jun 18 | 0 | -45 | 22 | 0 |
| 31 Mar 18 | 0 | -12 | 14 | 0 |
| 31 Dec 17 | 0 | -14 | 10 | 0 |
| 30 Sep 17 | 2 | -8 | 8 | 0 |
| 30 Jun 17 | 1 | -8 | 7 | 0 |
| 31 Mar 17 | 1 | -6 | 5 | 0 |
| 31 Dec 16 | 0 | -5 | 4 | 0 |
| 30 Sep 16 | 0 | -4 | 4 | 0 |
| 31 Dec 15 | 0 | -1 | 1 | 0 |
Quality Earnings: IAN is currently unprofitable.
Growing Profit Margin: IAN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IAN is unprofitable, but has reduced losses over the past 5 years at a rate of 20.3% per year.
Accelerating Growth: Unable to compare IAN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IAN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).
Return on Equity
High ROE: IAN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.